by Jay Bitkower | Dec 27, 2022 | Therapeutics Updates
Dr. Toni Choueiri, the principal investigator, from Dana Farber Institute, presented the results of the much-anticipated Phase III trial, COSMIC-313, at the 2022 European Society for Medical Oncology (ESMO) Conference in Paris. COSMIC-313 is the first triplet drug...
by Jay Bitkower | Dec 20, 2022 | Therapeutics Updates
The following is a summary extracted from a set of guidelines issued during 2022 by the American Society for Clinical Oncology (ASCO) on how to medically treat metastatic kidney cancer for patients who have clear cell carcinoma (ccRCC). The guidelines were developed...
by Jay Bitkower | Jun 20, 2022 | Therapeutics Updates
Oncologists generally prescribe adjuvant therapy to patients who not only have been diagnosed and treated for their disease but, also have a high probability that the disease will return. For example, in women with hormone-receptor-positive (HR+), the most common...
by Jay Bitkower | Aug 28, 2020 | Therapeutics Updates
From October 2014 through June 2017, Bristol-Myers Squibb sponsored a Stage III trial, called CheckMate 214 (NCT02231749 on clinicaltrials.gov), testing the combination of therapies nivolumab (Opdivo) and ipilimumab (Yervoy) against sunitnib (Sutent) in...
by Jay Bitkower | Aug 25, 2020 | Therapeutics Updates
Introduction The FDA approved the combination therapy avelumab and axitinib for first-line treatment of metastatic kidney cancer patients on May 14, 2019 based on the results of a Phase III trial, Javelin 101 Renal, led by Toni Choueiri of Dana Farber Institute,...
by Jay Bitkower | May 14, 2019 | Therapeutics Updates
In a report delivered by Thomas Powles, from Queen Mary University, London, the combination therapy of pembrolizumab (Keytruda) and axitinib (Inlyta) had a superior performance, in a 861-patient trial, to sunitinib (Sutent), the current standard of care therapy given...
